Medical AI startup Boltz raises $110M to speed up small molecule research
Boltz PBC, a startup that develops artificial intelligence models for pharmaceutical researchers, has raised $110 million in funding. Bessemer led the Series A investment. Boltz stated on Wednesday that the fund was joined by a large group of new and returning backers. The consortium included Greycroft, Andreessen Horowitz, Amplify Partners, F-Prime Capital, Hummingbird and others. […] The post…
Boltz PBC, a medical AI startup, has successfully raised $110 million in funding to accelerate small molecule research. The Series A investment was led by Bessemer, with additional support from other prominent investors including Greycroft, Andreessen Horowitz, Amplify Partners, F-Prime Capital, and Hummingbird. Small molecules, essential building blocks for many drugs, require researchers to identify molecules that effectively bind to pathogens.
This identification process typically involves evaluating hundreds of thousands of candidate molecules, a time-consuming and expensive endeavor. Boltz aims to streamline this workflow by offering an AI model called BoltzMol-1. Instead of reviewing numerous molecules, BoltzMol-1 generates binding affinity data for just a few dozen promising candidates.
The fewer molecules that need to be studied, the less time the analysis takes. The AI model generates small molecule hits, which are data points that help researchers narrow down their focus. Of the six targets explored by BoltzMol-1, it successfully identified small molecule hits for five of them. Boltz also offers a second model, BoltzProt-1, which generates hundreds of thousands of protein designs based on the small molecule hits.
Unlike other AI models that use indirect evaluation metrics for protein designs, BoltzProt-1 employs more direct metrics, demonstrating higher success in internal tests. Customers can access Boltz's algorithms through an application programming interface (API) that charges based on token usage. Since the launch of BoltzMol-1 and BoltzProt-1 in June, customers' token consumption has increased by a factor of 50.
Notable pharmaceutical companies, comprising six of the world's top 20, are among Boltz's clients. With the new funding, the company plans to expand its workforce and acquire more computing infrastructure to keep pace with leading AI labs like Anthropic and OpenAI. Boltz is currently developing new generation algorithms for molecule design, which have shown substantial improvements over its existing models.
Written by urgent.news from SiliconANGLE's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.